TY - JOUR T1 - A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. AU - Yang,Jingyun, AU - Wang,Wei, AU - Chen,Zimin, AU - Lu,Shuaiyao, AU - Yang,Fanli, AU - Bi,Zhenfei, AU - Bao,Linlin, AU - Mo,Fei, AU - Li,Xue, AU - Huang,Yong, AU - Hong,Weiqi, AU - Yang,Yun, AU - Zhao,Yuan, AU - Ye,Fei, AU - Lin,Sheng, AU - Deng,Wei, AU - Chen,Hua, AU - Lei,Hong, AU - Zhang,Ziqi, AU - Luo,Min, AU - Gao,Hong, AU - Zheng,Yue, AU - Gong,Yanqiu, AU - Jiang,Xiaohua, AU - Xu,Yanfeng, AU - Lv,Qi, AU - Li,Dan, AU - Wang,Manni, AU - Li,Fengdi, AU - Wang,Shunyi, AU - Wang,Guanpeng, AU - Yu,Pin, AU - Qu,Yajin, AU - Yang,Li, AU - Deng,Hongxin, AU - Tong,Aiping, AU - Li,Jiong, AU - Wang,Zhenling, AU - Yang,Jinliang, AU - Shen,Guobo, AU - Zhao,Zhiwei, AU - Li,Yuhua, AU - Luo,Jingwen, AU - Liu,Hongqi, AU - Yu,Wenhai, AU - Yang,Mengli, AU - Xu,Jingwen, AU - Wang,Junbin, AU - Li,Haiyan, AU - Wang,Haixuan, AU - Kuang,Dexuan, AU - Lin,Panpan, AU - Hu,Zhengtao, AU - Guo,Wei, AU - Cheng,Wei, AU - He,Yanlin, AU - Song,Xiangrong, AU - Chen,Chong, AU - Xue,Zhihong, AU - Yao,Shaohua, AU - Chen,Lu, AU - Ma,Xuelei, AU - Chen,Siyuan, AU - Gou,Maling, AU - Huang,Weijin, AU - Wang,Youchun, AU - Fan,Changfa, AU - Tian,Zhixin, AU - Shi,Ming, AU - Wang,Fu-Sheng, AU - Dai,Lunzhi, AU - Wu,Min, AU - Li,Gen, AU - Wang,Guangyu, AU - Peng,Yong, AU - Qian,Zhiyong, AU - Huang,Canhua, AU - Lau,Johnson Yiu-Nam, AU - Yang,Zhenglin, AU - Wei,Yuquan, AU - Cen,Xiaobo, AU - Peng,Xiaozhong, AU - Qin,Chuan, AU - Zhang,Kang, AU - Lu,Guangwen, AU - Wei,Xiawei, Y1 - 2020/07/29/ PY - 2020/03/17/received PY - 2020/07/23/accepted PY - 2020/7/30/pubmed PY - 2020/10/30/medline PY - 2020/7/30/entrez SP - 572 EP - 577 JF - Nature JO - Nature VL - 586 IS - 7830 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory disease called coronavirus disease 2019 (COVID-19), the spread of which has led to a pandemic. An effective preventive vaccine against this virus is urgently needed. As an essential step during infection, SARS-CoV-2 uses the receptor-binding domain (RBD) of the spike protein to engage with the receptor angiotensin-converting enzyme 2 (ACE2) on host cells1,2. Here we show that a recombinant vaccine that comprises residues 319-545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after the injection of a single vaccine dose. The sera from the immunized animals blocked the binding of the RBD to ACE2, which is expressed on the cell surface, and neutralized infection with a SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Notably, vaccination also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. We found increased levels of RBD-specific antibodies in the sera of patients with COVID-19. We show that several immune pathways and CD4 T lymphocytes are involved in the induction of the vaccine antibody response. Our findings highlight the importance of the RBD domain in the design of SARS-CoV-2 vaccines and provide a rationale for the development of a protective vaccine through the induction of antibodies against the RBD domain. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/32726802/A_vaccine_targeting_the_RBD_of_the_S_protein_of_SARS_CoV_2_induces_protective_immunity_ DB - PRIME DP - Unbound Medicine ER -